Houston Methodist is once again the top hospital in Texas. Photo via Houston Methodist

U.S. News & World Report has released its 2025 rankings of the best hospitals in Texas, and they prove that Houston is in good hands.

The esteemed Houston Methodist Hospital was rated the No. 1 best hospital in Texas for the 14th consecutive year, and the No. 1 hospital in the metro area. Eleven more Houston-area hospitals earned spots among the statewide top 35.

U.S. News annually evaluates 581 Texas hospitals to determine which meet the publication's rigorous standards and offer the best care for patients. Hospitals are also ranked among 15 specialties, including cancer, cardiology, heart and vascular surgery, obstetrics and gynecology, orthopedics, psychiatry, rehabilitation, diabetes and endocrinology, and more.

Houston Methodist also appeared on U.S. News' prestigious list of Honor Roll hospitals, consisting of 20 medical centers that are deemed the "best of the best" hospitals in the nation. No other Texas hospitals made the list, further proving that Houston Methodist takes exceptional care of its patients.

"This is a tremendous achievement for our physicians and employees who dedicate themselves every day to our patients," said Marc Boom, M.D., president and CEO of Houston Methodist, in a press release. "We take pride in these national recognitions but more importantly, these accolades reflect our unparalleled commitment to keeping our patients at the center of everything we do."

Houston Methodist earned several top-20 rankings across 11 of the 15 total specialties nationwide. It also earned national recognition for having the 7th best gastroenterology/GI surgery program, the 8th best pulmonology and lung surgery programs, and the 10th best diabetes and endocrinology programs in the country.

Elsewhere in Houston, The University of Texas MD Anderson Cancer Center ranked as the No. 1 best cancer hospital in the nation for the 11th year in a row.

"We are honored to again be ranked as the nation’s top hospital for cancer care – a recognition that reaffirms our commitment to our shared mission to end cancer," said MD Anderson president Peter WT Pisters, M.D., in a release. "We are grateful to every one of our teammates, trainees, students, donors, volunteers, advocates and patients, whose unwavering dedication make it possible for MD Anderson to deliver outstanding patient care."

Other top-performing Houston-area hospitals that ranked among the best in Texas include:

  • No. 4 – Baylor St. Luke's Medical Center
  • No. 5 – Memorial Hermann Greater Heights Hospital
  • No. 6 – Memorial Hermann Hospital
  • No. 8 – Houston Methodist Sugar Land Hospital
  • No. 9 – Houston Methodist Willowbrook Hospital
  • No. 12 – Houston Methodist The Woodlands Hospital
  • No. 13 – Memorial Hermann Memorial City Medical Center (tied with Baylor Scott and White All Saints Medical Center - Fort Worth)
  • No. 21 – Houston Methdodist Baytown Hospital (tied with Methodist Hospital - Stone Oak in San Antonio and Texas Health Harris Methodist Hospital Fort Worth)
  • No. 25 – HCA Houston Healthcare Clear Lake in Webster (tied with St. Luke's Health - The Woodlands Hospital, Baylor Scott and White Medical Center - Round Rock-Lakeway, and Texas Health Presbyterian Hospital Plano)
  • No. 29 – University of Texas Medical Branch in Galveston (tied with Medical City Plano)
---

This article originally appeared on CultureMap.com.

The merger that would have created the largest hospital system in Texas has been called off. Photo via memorialhermann.org

Major Texas hospital merger between Memorial Hermann and Baylor Scott & White called off

Discharged

Two Texas hospitals that were headed for union have called off their engagement plans, according to a joint statement. Dallas-based Baylor Scott and White and Houston-based Memorial Hermann announced in October that they were on track to combine forces following a letter of intent to merge and create a combined system.

The merger would have created a system with over 68 hospital campuses, 1,100 care delivery sites, almost 14,000 physicians, and serve almost 10 million patients each year, according to the October release. The more formalized agreement was expected this year.

"After months of thoughtful exploration, we have decided to discontinue talks of a merger between our two systems," the February 5 release states. "Ultimately, we have concluded that as strong, successful organizations, we are capable of achieving our visions for the future without merging at this time."

Jim Hinton, current CEO of Baylor Scott and White, was announced to be the system's CEO. Chuck Stokes, president and CEO of Memorial Hermann, was said to serve in the proposed office of the CEO, along with Baylor Scott and White president, Pete McCanna.

"We have a tremendous amount of respect for each other and remain committed to strengthening our communities, advancing the health of Texans and transforming the delivery of care," the release continues. "We will continue to seek opportunities for collaboration as two forward-thinking, mission-driven organizations."

This story will be updated as more information becomes available.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.